---
title: "Keen Vision Acquisition | 10-Q: FY2025 Q2 EPS: USD 0.2"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252546283.md"
datetime: "2025-08-11T20:01:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252546283.md)
  - [en](https://longbridge.com/en/news/252546283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252546283.md)
generator: "portal-rs"
---

# Keen Vision Acquisition | 10-Q: FY2025 Q2 EPS: USD 0.2

EPS: As of FY2025 Q2, the actual value is USD 0.2.

### Segment Revenue

-   **Dividend Income**: For the six months ended June 30, 2025, dividend income earned in investments held in the Trust Account was $1,489,599, compared to $3,530,524 for the same period in 2024.

### Operational Metrics

-   **Net Income**: For the six months ended June 30, 2025, net income was $1,126,226, compared to $5,040,728 for the same period in 2024.
-   **Formation and Operating Costs**: For the six months ended June 30, 2025, formation and operating costs were - $363,373, compared to - $533,783 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was - $486,853, compared to - $370,399 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: For the six months ended June 30, 2025, net cash used in investing activities was - $1,200,000.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $1,633,622.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focused on completing a business combination by August 27, 2025, with the possibility of extending the deadline further. The company has entered into a merger agreement with Medera Inc., a clinical stage biopharmaceutical company, with a net value of $622,560,000 for Medera’s shares.
-   **Non-Core Business**: The company has not commenced any operations and is focused on identifying a potential target for a business combination. The company will not generate operating revenues until after the completion of a business combination.

### Related Stocks

- [KVAC.US](https://longbridge.com/en/quote/KVAC.US.md)
- [KVACF.US](https://longbridge.com/en/quote/KVACF.US.md)

## Related News & Research

- [‘The Time Has Come,’ Says Top Investor About Rocket Lab Stock](https://longbridge.com/en/news/305860342.md)
- [AI’s 48-Hour Stress Test Starts Now](https://longbridge.com/en/news/305878236.md)
- [INSTANT VIEW-Nvidia earnings beat estimates; attention turns to call](https://longbridge.com/en/news/305875718.md)
- [Nvidia has lost $2 trillion in value. Here's what options traders expect from earnings](https://longbridge.com/en/news/305815593.md)
- [BREAKINGVIEWS-Nine questions for Nvidia’s stand-in CEO](https://longbridge.com/en/news/305850075.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**